Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 Inhibitor Rechallenge in Advanced Solid Tumors
NCT05325684Phase 2Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab, atezolizumab in solid tumor (advanced stage), sponsored by The Affiliated Hospital of Qingdao University. Status: unknown.
02
Drugs
durvalumabatezolizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05325684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325684.